The effect of PADs on modulating EV signatures in cancer cells has been highlighted in a number of studies, assessing both pan-PAD inhibitor Cl-amidine as well as PAD2, PAD3, and PAD4 isozyme-specific inhibitors [11,12,15,17]. The gene discussed is PADI3; the disease is cancer.